Potential role of amino acids in pathogenesis of schizophrenia

Shamaila Saleem¹, Faiza Shaukat², Anjuman Gul³, Mahwish Arooj⁴, Arif Malik⁵

¹Department of Physiology, College of Medicine, Qassim University, Kingdom of Saudi Arabia, ²Department of Community Medicine, College of Medicine, Qassim University, Kingdom of Saudi Arabia, ³Department of Biochemistry, College of Medicine, Qassim University, Kingdom of Saudi Arabia, ⁴University College of Medicine and Dentistry (UCMD), University of Lahore, Pakistan, ⁵Institute of Molecular Biology and Biotechnology (IMBB) (CRiMM), The University of Lahore, Pakistan

Address for correspondence:
Dr. Shamaila Saleem, Department of Physiology, College of Medicine, Qassim University, Kingdom of Saudi Arabia. Phone: 0552669180. E-mail: shamailasaleem@qumed.edu.sa

ABSTRACT

Schizophrenia is a syndrome of inconclusive etiopathogenesis with a prevalence of about 1% in general population. Underlying factors include genetic predisposition and defected neurodevelopment in early stages of life. The role of amino acids has been indicated in some reports. However, very few workers have detailed the effect of each amino acid in the pathophysiology of schizophrenia. Thus, in the present review, we aimed to provide an insight into the potential role of amino acids levels during schizophrenia. Any single amino acid defect cannot lead to the development of the disease. Higher concentration of glycine, serine, glutamate, homocysteine, and arginine are reported by many scientists in blood samples of patients of schizophrenia. Levels of rest of the amino acids show inconsistent results. Involvement of glutamate in pathophysiology of schizophrenia was hypothesized as early as the 1980s. It was demonstrated that dissociative anesthetics which are N-methyl-D-aspartate (NMDA) receptor antagonists can produce all negative, psychotic, cognitive, and physiological features of schizophrenia in healthy controls. This led to the development of hypothesis of NMDA receptor hypofunctioning in the pathophysiology of schizophrenia. Later on, it was also found that agents enhancing functioning of NMDA receptor at glycine modulatory site, improved symptoms in patients of schizophrenia receiving antipsychotic medications. Thus, the relationship of perturb amino acid levels with the biological basis and pathophysiology of schizophrenia is an important area to be further explored for effective management of schizophrenic patients.

Keyword: Amino acids, arginine, glutamate, glycine, homocysteine, N-methyl-D-aspartate receptor, schizophrenia, serine

Introduction

Schizophrenia is a chronic devitalizing disease, affecting around 1% of population.¹ The various factors causing schizophrenia includes genetic predisposition and defected neurodevelopment in early stages of life. There are evidences that some complications in pregnancy and perinatal period can lead to subsequent schizophrenia in life. They may include any infection in second trimester of pregnancy, obstetric complication, starvation of baby in uterus, and decreased nutritional supply to the fetus as in preeclampsia.² Its symptoms can be broadly divided to positive and negative ones. Positive symptoms include delusions, hallucinations and paranoia and main negative symptoms are weakened or exhausted speech, decrease motivation, community withdrawal, and blunted effects.³ Disease starts appearing in early adulthood and symptoms usually persist till later life, despite active treatment.⁴ Such a prolonged course of illness leads not only to personal disability and distress but also a great burden to society costing about 11.8 billion pounds per annum.⁵ Complicating further the situation, the disease is associated with anxiety, depression and addiction,⁶ chronic obstructive pulmonary disease, asthma, Type 2 diabetes, and related complications.⁷ Mortality in these patients is higher because of high incidence of ischemic heart disease and cancer.¹⁰,¹¹

Etiology includes genetic factors, some predisposing factors and lifestyle changes. Antipsychotic drugs given to treat the condition further worsen the situation.¹² Dopaminergic pathway is found to be disturbed in these patients but the disease is complicated by the presence of oxidative stress, atypical immune-mediated responses¹³ and thyroid disturbances.¹⁴ Such a diversified pathophysiology can be treated by the strategy of adjuvant nutritional therapy along with usual course of treatment.¹³

Schizophrenic patients, mostly live away from home in a very desperate environment. Hence, they have poor physical health¹⁵ and die early because of cardiovascular diseases,¹⁶ poor diet, obesity, physical inactivity, and smoking.¹⁷ Gillman have suggested that an increased intake of fresh fruits plus vegetables can decrease the risk of cardiovascular disease.¹⁸
Possible three reasons can be given to answer the question of why schizophrenic patients have poor diet. First of all, they are unemployed. Second, mostly they become smokers and even in general population, diet of smokers is worse than that of non-smokers. Third, apathy, a negative symptom of schizophrenia can lead to consumption of less healthy, more convenient food.  

It is well known that nutritional status of the patient is very important in etiology of physical diseases such as cardiovascular diseases, diabetes, and cancer but very little research is available regarding relationship of mental illness and nutrition. Some previous researchers have reported that there is some relationship between dietary fats and poor outcome in schizophrenic patients. These patients are having severe oxidative stress as there is actually imbalance between production of reactive oxygen species/reactive nitrogen species and antioxidants. This oxidative stress is further complicated by a number of pathophysiological mechanisms such as mitochondrial dysfunction, inflammation, lipid peroxidation, DNA damage, and apoptosis. Thus, antioxidant treatment can be adopted as adjuvant therapy in these patients. Glutathione is an important antioxidant; decreased in brains of these patients. N-acetyl cysteine (NAC) has been proven to increase plasma glutathione level in schizophrenic patients. Alpha lipoic acid is another strong antioxidant having similar functions to glutathione, can cross blood–brain barrier. Melatonin is another effective antioxidant can scavenge free radicals ameliorating symptoms of the disease. Researchers have also highlighted the effectiveness of essential polyunsaturated fatty acids supplementation in schizophrenic patients. Among non-enzymatic antioxidants, vitamin C and E are helpful in breaking free radical chain reactions in patients of schizophrenia. L-theanine (a gamma-glutamylethylamide) an important amino acid found in tea plant is an antioxidant as it has ability to inhibit lipid peroxidation. It also reduces adverse effects induced by doxorubicin leading to oxidative damage. Hypofunctioning of N-methyl-D-aspartate (NMDA) glutamate receptor might be involved in the pathophysiology of schizophrenia. Therapeutic administration of certain amino acids, involving NMDA receptor has led to the improvement of symptoms of schizophrenia. For example, glycine, D-cycloserine, D-serine, all of which act as co-agonist at NMDA receptor can lead to improvement in negative symptoms in patients of schizophrenia. Biogenic amines such as noradrenaline, serotonin, dopamine, and histamine are synthesized from their precursors, tryptophan, tyrosine, and histidine. Levels of these amino acids precursors in central nervous system is dependent on blood concentration of phenylalanine, valine leucine and isoleucine, have affinity for tyrosine and tryptophan carriers, to cross blood–brain barrier. Certain other amino acids such as serine, glycine, aspartic, and glutamic acid act as neurotransmitters and aid in neuronal development. An imbalance of these neurotransmitter levels have been reported in patients of schizophrenia. Changes in plasma concentration of these amino acids, might increase susceptibility of such a psychotic disorder, thus can also influence treatment outcome. From these studies, the role of nutritional status with the genesis of schizophrenia has been indicated in some reports. However, very few workers have detailed the effect of each amino acid in the pathophysiology of schizophrenia. Thus, in the present review, we aimed to provide an insight into the potential role of amino acids levels during schizophrenia. This review may help in developing combination therapies targeting multifactorial schizophrenia pathophysiologies along with normal treatment therapy.

**Literature Review**

In past few years, increasing interest has been observed in finding out possible role of amino acids in the pathophysiology of schizophrenia. Most of the research is focused on glutamate and gamma amino butyric acid (GABA) but some role is also played by other amino acids as well. Tyrosine is a non-essential aromatic amino acid, a precursor of nor-epinephrine, epinephrine, and dopamine. Vincenzo et al. found a high serum tyrosine concentration in schizophrenic patients treated with clozapine. They also found lower tryptophan concentration also lower tryptopahn to large neutral amino acid ratio in the serum of schizophrenic patients. Various studies reported low serum tryptophan levels in patients of schizophrenia. It can lead to decreased uptake of tryptophan by neurons of brain leading to decreased serotonin levels in the brain of schizophrenic patients as tryptophan is a serotonin precursor. They also found that with clozapine treatment levels of tryptophan start improving day-by-day with improvement of condition of the patient. Alfredsson et al. also found increasing tryptophan levels in early part of their treatment of patients of schizophrenia. L-serine is another amino acid which acts as cotransmitter to regulate NMDA glutamate receptor. Macciardi et al. reported that there is increased level of serine in serum as well as in brain of patients of schizophrenia, they found that there must be a correlation between elevated serine level and pathophysiology of schizophrenia. Some other researchers reported normal serine plasma levels in patients of schizophrenia. In contrast, Tortorella et al. have reported lower serum serine levels in drug-free schizophrenic patients. D-serine is another co-agonist at NMDA receptor. To open NMDA receptor, glutamate has to bind to NR2 receptor site. Glycine and serine have to bind to NR1 receptor site. D-serine is more permeable to blood–brain barrier also has more affinity to NMDA receptor compared to glycine. Thus, lesser doses
of D-serine would be more effective. Panizzutti et al. have observed increasing activation of hippocampus, enhancement of learning process, increased long-term potentiation after administration of D-serine in patients of schizophrenia. Hashimoto et al. found lower levels of D-serine in serum of schizophrenic patients if we compare them with control groups. There can be deficiency of serine racemase enzyme which converts L-serine to D-serine in patients of schizophrenia or overactivity of enzyme D-amino oxidase which leads to increase catabolism of D-serine. Ohnuma et al. observed improvement in the levels of D-serine as well as D/L serine ratio in clinically improving patients of schizophrenia. Labrie et al. have reported schizophrenia-like behavior in mutant mice, in which there is loss of enzyme serine racemase resulting in decrease D-serine levels in brain.

L-glutamine is a non-essential amino acid. Alfredsson et al. found a negative correlation between serum glutamine levels with clinical response to treatment.

L-asparagine: Tortorella et al. found lower serum asparagines levels in schizophrenic patients as compared to control group whereas Rao et al. reported higher serum asparagines levels in drug-free schizophrenic patients as compared to healthy controls.

L-glutamate is a well-known excitatory, non-essential amino acid. Tortorella et al. found elevated glutamate levels in serum of patients of schizophrenia which are found to be decreased by treatment with clozapine. Similarly, Macciardi et al. also reported higher glutamate levels in the serum of patients of schizophrenia. Tomiya et al. have reported rise in serum glutamate levels only in male patients of schizophrenia. According to Evins et al., longterm treatment with clozapine leads to increase in serum glutamate levels. Glutamatergic hypothesis of schizophrenia states that levels of glutamate are lower in patients of schizophrenia and a good antipsychotic medicine can act as enhancer of glutamatergic neurotransmission. According to some researchers, peripheral level of glutamate cannot reflect its level in brain as it is synthesized in central nervous system; however, many others have reported a positive correlation between serum glutamate level with its level in cerebral spinal fluid.

L-aspartate is another non-essential amino acid. Tortorella et al. have reported higher serum aspartate levels in drug-free schizophrenic patients. Evins et al. have shown that clozapine administration increases basal serum aspartate level (Table 1).

Glycine is a non-essential amino acid, an inhibitory neurotransmitter which regulates the activity of NMDA receptor. Some researchers have reported elevated serum glycine concentration in patients of schizophrenia compared to healthy controls. Some researchers have reported decreased plasma glycine levels in schizophrenic patients, seeming to relate the severity of negative symptoms in patients of schizophrenia with their response to drugs such as clozapine. Genetic plus drug-induced deficiency in glycine binding as observed in experimental mice leads to certain behavioral changes which appear to be responsible for cognitive and negative symptoms of schizophrenia. According to some researchers, administering glycine with some antipsychotics or administrating glycine transport inhibitors (GTI), with or without glycine, have promising results in the treatment of schizophrenia. GTI when given together with glycine, less doses of glycine are required because it activates glycine modulatory sites at NMDA receptor, thus inhibits removal of glycine from synaptic cleft region, elevating its levels.

L-proline is an essential amino acid. According to Jacquet et al., increased proline level is a risk factor for development of schizophrenia. Raux et al. have reported that patients of velocardiofacial-syndrome which is a syndrome associated with schizophrenia, have shown hyperprolinemia.

Table 1: Altered levels of different amino acids are shown in schizophrenic patients

| Amino acids | Levels in schizophrenia patients | Authors |
|-------------|----------------------------------|---------|
| Homocysteine | ↑                                | Moustafa et al. 2015, Kevere et al. 2012, Muntjewerff et al. 2006 |
| Glycine     | ↑                                | Baruah et al. 1991, Macciardi et al. 1990 ↓ | Hons et al. 2010, Neeman et al. 2005, Sumiyoshi et al. 2004 |
| Tyrosine    | ↑ (in clozapine treated)         | Vincenzo et al. 2008 |
| Tryptophan  | ↑                                | Vincenzo et al. 2008 ↓ | Tortorella et al. 2001, Rao et al. 1990, Alfredsson et al. 1990 |
| L-glutamate | ↑ (in male pts only)             | Tomiya et al. 2007 ↑ | Tortorella et al. 2001, Macciardi et al. 1990 |
| L-proline   | ↑                                | Jacquet et al. 2005 |
| L-isoleucine| ↑                                | Tortorella et al. 2001 |
| L-aspartate | ↑                                | Tortorella et al. 2001 ↑ | (in clozapine-treated) Evins et al. 1997 |
| L-asparagine| ↓                                | Tortorella et al. 2001 ↑ | Rao et al. 1990 |
| L-serine    | ↓                                | Tortorella et al. 2001 ↑ | Macciardi et al. 1990 |
| Histidine   | ↑                                | Carl et al. 1992 |
| Arginine    | ↑                                | Carl et al. 1992 |
| Cysteine    | ↓                                | Rao et al. 1990 |
| Citrulline  | ↑                                | Rao et al. 1990 |
| L-glutamine | ↑                                | Alfredsson et al. 1990 |
L-isoleucine is also an essential amino acid and competes with tyrosine and tryptophan for binding with transporters to cross blood–brain barrier. Researchers have found higher serum isoleucine levels in patients of schizophrenia. Similarly, Carl et al. have reported higher serum histidine and arginine levels in patients of schizophrenia.

Rao et al. have reported lower levels of cysteine and higher levels of citrulline in drug-free schizophrenic patients. Similarly, a detailed meta-analysis showed that the levels of homocysteine (Hcy) are higher in patients of schizophrenia as compared to healthy controls. Furthermore, according to Tomiya, serum level of ornithine is positively correlated with duration of illness of schizophrenic patients. Perry et al. have reported an irregular high fasting plasma ornithine concentration in patients of acute psychosis.

L-arginine is a precursor of nitric oxide (NO). It effects levels of dopamine, GABA, and Glutamate in prefrontal cortex of brain. It also has a role in memory and learning. NO levels are found to be raised in the brains of awake and mobile animals after phencyclidine (PCP) treatment. If together with PCP a nitric acid synthase inhibitor is administered, it not only reduce brain NO level but also PCP induce behavioral effects. Feigin et al. have also reported that cognitive dysfunction seen in schizophrenia patients may be reduced by using NOS inhibitors as a treatment approach. Contrary to this, some animal studies have reported that under production of NO may have some link with schizophrenia. As for example according to some researchers, NO donors (molsidomine and sodium nitroprusside) can alleviate behavioral effects induced by PCP.

A non-protein amino acid, Hcy is also found to be involved in the etiology of schizophrenia. It is produced in the cell during one carbon metabolism. In the past researchers have related raised Hcy levels with a lot of physical diseases (cardiovascular diseases). In recent years, it is found that there is some link between elevated Hcy and psychiatric diseases such as schizophrenia and affective disorders, as raised Hcy causes cognitive impairment, characteristic of most of the psychiatric disorders, especially schizophrenia. It acts by causing oxidative stress in cells by interacting with NMDA receptor leading to vascular damage, mitochondrial dysfunction, and apoptosis. Therapeutic supplementation of folic acid plus vitamin B can effectively reduce raised serum Hcy levels.

Kevere et al. also concluded that raised Hcy levels in patients of mood disorders and schizophrenia are linked to course and effect of the disease, suggesting it to be an important prognostic marker of psychiatric disorder, including schizophrenia.

Recently, many authors have emphasized that if schizophrenic patients are treated with amino acids supplements, their symptoms improve. For example, Wass et al. suggested that disturbed NO signaling is involved in the pathophysiology of schizophrenia. L-lysine is an amino acid which interferes with NO production. He concluded that 6 g/day treatment of L-lysine for about 4 weeks significantly decreased positive symptoms of schizophrenia. Similarly, according to Giorlando et al., NAC is an important emerging agent which can be used in therapy of different psychiatric disorders such as compulsive and grooming disorders, addiction, schizophrenia, and bipolar disorders. NAC exerts its affects by modulating inflammatory, neurotropic, and glutamatergic pathways. It is also precursor of glutathione which is an important antioxidant for the body.

Many authors have highlighted the role of amino acids and other antioxidants as alternative and complementary treatment for schizophrenia. For example, according to Arroll et al., schizophrenic patients can be given L-theanine (an amino acid of plant origin), NAC, vitamin B12, folic acid, pyridoxine, and essential polyunsaturated fatty acids along with regular medical care. L-theanine will reduce positive symptoms of schizophrenia, vitamin B6, B9, and B12 will reduce Hcy levels and polyunsaturated fatty acid will reduce fatty acid levels in the brain of such patients. Similarly, Lakan and Vieira suggested that not only tryptophan and glycine would be beneficial for schizophrenic patients but also Veg EPA capsule, containing omega 3 fish oil plus vitamin E as antioxidant, can be helpful in balancing the mood of such patients.

**Conclusion**

Disturbance in amino acid levels has been linked to pathophysiology of schizophrenia, in many recent studies. Amino acids (glycine, serine, glutamate, cysteine) have important role to play in mitochondria of astrocytes, not only in metabolism of Hcy but also in formation of glutathione. Disturbed Hcy levels can lead to vascular damage, DNA damage, and apoptosis in the brain of schizophrenic patients. Deficiency of glutathione, an important antioxidant can lead to increase ROS, leading to DNA damage and can cause lipid peroxidation of membrane of mitochondria in astrocytes. Increase membrane fluidity will not only disturb membrane transport but also mitochondrial enzymes in the brain of patients of schizophrenia. Thus, relationship of disturbed amino acid levels and schizophrenia is a new era to be further explored to manage schizophrenic patients effectively. As many antipsychotic medicines are having side effects, reducing dosage of these medicines, and adding amino acids, vitamins and other anti-oxidants in regular medical care of these patients would be really beneficial in long term.

**References**

1. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: The distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004;2:13.

2. Wahlbeck K, Forsén T, Osmund C, Barker DJ, Eriksson JG. Association of schizophrenia with low maternal body mass index,
small size at birth, and thinness during childhood. Arch Gen Psychiatry 2001;58:48-52.

3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM). Washington, DC: American Psychiatric Association; 1994. p. 143-7.

4. Häfner H, Maurer K, Löfler W, Riecher-Rössler A. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 1993;162:80-6.

5. Petronis A. The origin of schizophrenia: Genetic thesis, epigenetic antithesis, and resolving synthesis. Biol Psychiatry 2004;55:965-70.

6. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry 1991;48:239-46.

7. Andrew A, Knapp M, McCrone PR, Parsonage M, Trachtenberg M. Effective Interventions in Schizophrenia. The Economic Case; 2012.

8. Tsai J, Rosenheck RA. Psychiatric comorbidity among adults with schizophrenia: A latent class analysis. Psychiatry Res 2013;210:16-20.

9. Schöpf D, Uppal H, Potluri R, Reun R. Physical comorbidity and its relevance on mortality in schizophrenia: A naturalistic 12-year follow-up in general hospital admissions. Eur Arch Psychiatry Clin Neurosci 2014;264:3-28.

10. Crump C, Winkley MA, Sundquist K, Sundquist J. Mortality and causes of death in first admitted schizophrenia patients: A Swedish national cohort study. Am J Psychiatry 2013;170:324-33.

11. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115-21.

12. Aquila R. Management of weight gain in patients with schizophrenia. J Clin Psychiatry 2002;63 Suppl 4:33-6.

13. Arroll MA, Wilder L, Neil J. Nutritional interventions for the adjunctive treatment of schizophrenia: A brief review. Nutr J 2014;13:91.

14. Santos NC, Costa P, Ruano D, Macedo A, Soares MJ, Valente J, et al. Revisiting thyroid hormones in schizophrenia. J Thyroid Res 2012;2012:569147.

15. Anderson R. Physical health of people with severe mental illness. Health 2000;320:77.

16. Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 1993;163:183-9.

17. McCreadie RG. Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: Descriptive study. Br J Psychiatry 2003;183:534-9.

18. Gillman MW. Enjoy your fruits and vegetables. BMJ 1996;313:765-6.

19. Peet M. International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: An ecological analysis. Br J Psychiatry 2004;184:404-8.

20. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: The metabolic syndrome. Life Sci 2002;71:239-57.

21. Tucker KL, Buranapin S. Nutrition and aging in developing countries. J Nutr 2001;131:2417S-23.

22. Christensen O, Christensen E. Fat consumption and schizophrenia. Acta Psychiatr Scand 1988;78:587-91.

23. Peet M. Nutrition and schizophrenia: Beyond omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 2004;70:417-22.

24. Peet M, Edwards RW. Lipids, depression and physical diseases. Curr Opin Psychiatry 1997;10:477-80.

25. Kohen R, Nyska A. Invited review: Oxidation of biological systems: Oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol 2002;30:620-50.

26. Ciobica A, Padurariu M, Dobrin I, Stefanescu C, Dobrin R. Oxidative stress in schizophrenia - Focusing on the main markers. Psychiatr Danub 2011;23:237-45.

27. Wood SJ, Yücel M, Pantelis C, Berk M. Neurobiology of schizophrenia spectrum disorders: The role of oxidative stress. Ann Acad Med Singapore 2009;38:396-6.

28. Bitanihirwe BK, Woo TU. Oxidative stress in schizophrenia: An integrated approach. Neurosci Biobehav Rev 2011;35:878-93.

29. Lavoie S, Murray MM, Deppen P, Kyazavea MG, Berk M, Boulot O, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008;33:2187-99.

30. Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 1996;55:45-54.

31. Yokozawa T, Dong E. Influence of green tea and its three major components upon low-density lipoprotein oxidation. Exp Toxicol Pathol 1997;49:329-35.

32. Sugiyama T, Sadzuka Y. Theanine, a specific glutamate derivative in green tea, reduces the adverse reactions of doxorubicin by changing the glutathione level. Cancer Lett 2004;212:177-84.

33. Krebs MO. Glutamatergic hypothesis of schizophrenia: Psychoses induced by phenylcyclidine and cortical-subcortical imbalance. Encephale 1995;21:581-8.

34. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1007.

35. Ohnuma T, Sakai Y, Maeshima H, Hatano T, Hanzawa R, Abe S, et al. Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: Results from the Juntendo University Schizophrenia Projects (JUSP). Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1905-12.

36. Fernstrom JD, Faller DV. Neutral amino acids in the brain: Changes in response to food ingestion. J Neurochem 1978;30:1531-8.

37. Fernstrom JD. Dietary precursors and brain neurotransmitter formation. Annu Rev Med 1981;32:413-25.

38. Maycox PR, Helli JW, Jahn R. Amino acid neurotransmission: Spotlight on synaptic vesicles. Trends Neurosci 1990;13:83-7.

39. De Luca V, Viggiano E, Messina G, Viggiano A, Borlido C, Viggiano A, et al. Peripheral amino Acid levels in schizophrenia and antipsychotic treatment. Psychiatry Invest 2008;5:203-8.

40. Baker GB, Hallak JE, Dilullo AF, Burback L, Dursun SM. Amino acids in schizophrenia--glycine, serine and arginine. Handbook of Schizophrenia Spectrum Disorders. Vol. I. Netherlands: Springer; 2011. p. 253-62.

41. Rao ML, Gross G, Strebel B, Bräunig P, Huber G, Klosterkötter J. Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects. Psychiatry Res 1990;34:243-57.

42. Tortorella A, Monteleone P, Fabrazzo M, Viggiano A, De Luca L, Maj M. Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiology 2001;44:167-71.

43. Alfredsson G, Wiesel FA. Relationships between clinical effects and monoamine metabolites and amino acids in sulphiride-treated schizophrenic patients. Psychopharmacology (Berl) 1990;101:324-31.

44. Macciardi F, Lucca A, Catalano M, Marino C, Zanardi R, Smeraldi E. Amino acid patterns in schizophrenia–glycine, serine and arginine. Handbook of Amino acids in schizophrenia 2011. p. 253-62.

45. Saleem, et al.: Amino acids and Schizophrenia

46. Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia? Brain Res Bull 2010;83:108-21.

47. Wood SJ, Yücel M, Pantelis C, Berk M. Neurobiology of schizophrenia spectrum disorders: The role of oxidative stress. Ann Acad Med Singapore 2009;38:396-6.
Rudin M. The pharmacological stimulation of NMDA receptors via co-agonist site: An fMRI study in the rat brain. Neurosci Lett 2005;380:111-5.

48. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, et al. Decreased serum levels of D-serine in patients with schizophrenia: Evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003;60:572-6.

49. Labrie V, Fukumura R, Rastogi A, Fick LJ, Wang W, Boutros PC, et al. Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum Mol Genet 2009;18:3227-43.

50. Tomiya M, Fukushima T, Watanabe H, Fukami G, Fujisaki M, Iyo M, et al. Alterations in serum amino acid concentrations in male and female schizophrenic patients. Clin Chim Acta 2007;380:186-90.

51. Evins AE, Amico ET, Shih V, Goff DC. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J Neural Transm (Vienna) 1997;104:761-6.

52. Goff DC, Wine L. Glutamate in schizophrenia: Clinical and research implications. Schizophr Res 1997;27:157-68.

53. Baruah S, Waziri R, Hegwood TS, Mallis LM. Plasma serine in schizophrenics and controls measured by gas chromatography-mass spectrometry. Psychiatry Res 1991;37:261-70.

54. Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt DC, et al. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry 2005;162:1738-40.

55. Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: Relation to negative symptoms. Int J Neuropsychopharmac 2004;7:1-8.

56. Hons J, Zirk R, Ulychova M, Cermakova E, Dubek P, Libiger J. Glycine serum level in schizophrenia: Relation to negative symptoms. Psychiatry Res 2010;176:103-8.

57. Sumiyoshi T, Jin D, Jayathilake K, Lee M, Meltzer HY. Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia. Int J Neuropsychopharmacol 2005;8:451-5.

58. Labrie V, Lipina T, Roder JC. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 2008;200:217-30.

59. Boulay D, Bergis O, Avenet P, Griebel G. The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. Neuropsychopharmacology 2010;35:416-27.

60. Jacquet H, Domily C, Houy E, Hecketsweiler B, Bou J, Raux G, et al. Hyperprolinemia is a risk factor for schizoaffective disorder. Mol Psychiatry 2005;10:479-85.

61. Raux G, Bumsel E, Hecketsweiler B, van Amelsvoort T, Zinkstok J, Manouvrier-Hanu S, et al. Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome. Hum Mol Genet 2007;16:83-91.

62. Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: A meta-analysis. Mol Psychiatry 2006;11:143-9.

63. Perry TL, Wright JM, Hansen S. Hyperparaglinagia in a schizophrenic patient. Biol Psychiatry 1983;18:89-97.

64. Bernstein HG, Bogerts B, Keilhoff G. The many faces of nitric oxide in schizophrenia. A review. Schizophr Res 2005;78:69-86.

65. Pålsson E, Finnerty N, Feigin K, Klamer D, Wass C, Svensson L, et al. Increased cortical nitric oxide release after phencyclidine administration. Synapse 2009;63:1083-8.

66. Feigin K, Pålsson E, Wass C, Svensson L, Klamer D. Nitric oxide signaling in the medial prefrontal cortex is involved in the biochemical and behavioral effects of phencyclidine. Neuropsychopharmacology 2008;33:1874-83.

67. Bujas-Bohanovic M, Bird DC, Robertson HA, Dursun SM. Blockade of phencyclidine-induced effects by a nitric oxide donor. Br J Pharmacol 2000;130:1005-12.

68. Bujas-Bohanovic M, Robertson HA, Dursun SM. Effects of nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester on phencyclidine-induced effects in rats. Eur J Pharmacol 2000;409:57-65.

69. Moustafa AA, Hewedi DH, Eissa AM, Frydecka D, Misia B. Corrigendum: Homocysteine levels in schizophrenia and affective disorders-focus on cognition. Front Behav Neurosci 2015;9:81.

70. Kevere L, Purvina S, Bauze D, Zeibarts M, Andrezina R, Rizevs A, et al. Elevated serum levels of homocysteine and affective disorders: Focus on cognition. Front Behav Neurosci 2015;9:81.

71. Kevere L, Purvina S, Bauze D, Zeibarts M, Andrezina R, Rizevs A, et al. Elevated serum levels of homocysteine as an early prognostic factor of psychiatric disorders in children and adolescents. Schizophr Res Treatment 2012;2012:373261.

72. Wass C, Klamer D, Katsarogiannis E, Pålsson E, Svensson L, Feigin K, et al. L-lysine as adjunctive treatment in patients with schizophrenia: A single-blinded, randomized, cross-over pilot study. BMC Med 2011;9:40.

73. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011;36:78-86.

74. Lakhan SE, Vieira KF. Nutritional therapies for mental disorders. Nutr J 2008;7:2.